Literature DB >> 24379623

Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication.

Sang-Ho Park1, Napapan Kangwan1, Jong-Min Park1, Eun-Hee Kim1, Ki Baik Hahm1.   

Abstract

Although the International Agency for Research on Cancer declared Helicobacter pylori (H. pylori) as a definite human carcinogen in 1994, the Japanese Society for Helicobacter Research only recently (February 2013) adopted the position that H. pylori infection should be considered as an indication for either amelioration of chronic gastritis or for decreasing gastric cancer mortality. Japanese researchers have found that H. pylori eradication halts progressive mucosal damage and that successful eradication in patients with non-atrophic gastritis most likely prevents subsequent development of gastric cancer. However, those who have already developed atrophic gastritis/gastric atrophy retain potential risk factors for gastric cancer. Because chronic perpetuated progression of H. pylori-associated gastric inflammation is associated with increased morbidity culminating in gastric carcinogenesis, a non-microbial approach to treatment that provides long-term control of gastric inflammation through nutrients and other interventions may be an effective way to decrease this morbidity. This non-microbial approach might represent a new form of prerequisite "rescue" therapy that provides a quicker path to the prevention of gastric cancer as compared to simple eradication.

Entities:  

Keywords:  Atrophic gastritis; Gastric cancer; Helicobacter pylori; Non-microbial approach; Prevention

Mesh:

Substances:

Year:  2013        PMID: 24379623      PMCID: PMC3870551          DOI: 10.3748/wjg.v19.i47.8986

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  86 in total

1.  A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.

Authors:  X Calvet; N García; T López; J P Gisbert; E Gené; M Roque
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

Review 2.  Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids.

Authors:  Michael J Zhang; Matthew Spite
Journal:  Annu Rev Nutr       Date:  2012-03-09       Impact factor: 11.848

3.  Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.

Authors:  Frank Andersohn; René Schade; Samy Suissa; Edeltraut Garbe
Journal:  Stroke       Date:  2006-05-25       Impact factor: 7.914

4.  Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.

Authors:  J L Tong; Z H Ran; J Shen; C X Zhang; S D Xiao
Journal:  Aliment Pharmacol Ther       Date:  2007-01-15       Impact factor: 8.171

5.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

6.  The eradicating Helicobacter pylori infection in duodenal ulcer patients by three short-term triple therapies in China: a multicenter clinical comparative study.

Authors:  Wei-Qi Dai; Yin-Qun Zhou; Ling Xu; Bin-Fang Wang; Xiao-Ming Fan; Jian-Ye Wu; Chun-Yan Wang; Xuan-Fu Xu; Chuan-Yong Guo
Journal:  Hepatogastroenterology       Date:  2012 Jan-Feb

Review 7.  Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases.

Authors:  Robert Penner; Richard N Fedorak; Karen L Madsen
Journal:  Curr Opin Pharmacol       Date:  2005-10-07       Impact factor: 5.547

Review 8.  Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori.

Authors:  Sheila M Wilhelm; Jennifer L Johnson; Pramodini B Kale-Pradhan
Journal:  Ann Pharmacother       Date:  2011-06-21       Impact factor: 3.154

Review 9.  Clinical application of probiotics in the treatment of Helicobacter pylori infection--a brief review.

Authors:  Ami Patel; Nihir Shah; J B Prajapati
Journal:  J Microbiol Immunol Infect       Date:  2013-06-10       Impact factor: 4.399

Review 10.  Helicobacter pylori infection, oxidative DNA damage, gastric carcinogenesis, and reversibility by rebamipide.

Authors:  K B Hahm; K J Lee; J H Kim; S W Cho; M H Chung
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

View more
  4 in total

1.  Effects of Concurrent Omega-3 and Cranberry Juice Consumption Along with Standard Antibiotic Therapy on the Eradication of Helicobacter pylori, Gastrointestinal Symptoms, Some Serum Inflammatory and Oxidative Stress Markers in Adults with Helicobacter pylori Infection: A Study Protocol for a Randomized Controlled Trial.

Authors:  Ahmad Zare Javid; Leila Maghsoumi-Norouzabad; Hadi Bazyar; Vahideh Aghamohammadi; Pejman Alavinejad
Journal:  Infect Drug Resist       Date:  2020-09-15       Impact factor: 4.003

2.  Histopathological classification and follow-up analysis of chronic atrophic gastritis.

Authors:  Yang-Kun Wang; Lan Shen; Tian Yun; Bin-Feng Yang; Chao-Ya Zhu; Su-Nan Wang
Journal:  World J Clin Cases       Date:  2021-06-06       Impact factor: 1.337

Review 3.  Omega-3 Polyunsaturated Fatty Acids Intake to Regulate Helicobacter pylori-Associated Gastric Diseases as Nonantimicrobial Dietary Approach.

Authors:  Jong-Min Park; Migyeong Jeong; Eun-Hee Kim; Young-Min Han; Sung Hun Kwon; Ki-Baik Hahm
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

4.  Suppressed Helicobacter pylori-associated gastric tumorigenesis in Fat-1 transgenic mice producing endogenous ω-3 polyunsaturated fatty acids.

Authors:  Young-Min Han; Kyung-Jo Kim; Migyeung Jeong; Jong-Min Park; Eun-Jin Go; Jing X Kang; Sung Pyo Hong; Ki Baik Hahm
Journal:  Oncotarget       Date:  2016-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.